Typhoid vaccine development with a human challenge model

Affiliations

¹ Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK. Electronic address: nicholas.feasey@lstmed.ac.uk.
² Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.

Free article

Comment

Nicholas A Feasey et al. Lancet. 2017.

Free article

. 2017 Dec 2;390(10111):2419-2421.

doi: 10.1016/S0140-6736(17)32407-8. Epub 2017 Sep 28.

¹ Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK. Electronic address: nicholas.feasey@lstmed.ac.uk.
² Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.

No abstract available

Comment on

Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
Jin C, Gibani MM, Moore M, Juel HB, Jones E, Meiring J, Harris V, Gardner J, Nebykova A, Kerridge SA, Hill J, Thomaides-Brears H, Blohmke CJ, Yu LM, Angus B, Pollard AJ. Jin C, et al. Lancet. 2017 Dec 2;390(10111):2472-2480. doi: 10.1016/S0140-6736(17)32149-9. Epub 2017 Sep 28. Lancet. 2017. PMID: 28965718 Free PMC article. Clinical Trial.